What an FDA Drug Shortage Notice Actually Requires

A drug shortage notification isn’t a courtesy heads-up FDA appreciates receiving. Under Section 506C, it’s a legal obligation with a six-month clock attached, and the companies that treat it as optional paperwork are usually the ones who find out otherwise during an inspection.

In brief

Section 506C (21 U.S.C. § 356c) requires notifying FDA at least six months before permanently discontinuing manufacture, or before an interruption likely to cause a shortage, of certain drugs — or as soon as practicable if six months isn’t possible.
It applies to drugs FDA treats as life-supporting, life-sustaining, or intended to prevent or treat a debilitating disease or condition, plus any drug for which the notifying manufacturer is the sole source.
The 2012 FDA Safety and Innovation Act extended the obligation to every manufacturer of a covered drug, not only a sole manufacturer — “someone else probably makes it too” stopped being an exemption more than a decade ago.
The notice itself has required content: the reason for the discontinuation or interruption and its expected duration, not a one-line notice that a change is coming.

Who actually has to send this notice

The obligation attaches to the category of drug, not to how big the manufacturer is. A product FDA has designated life-supporting or life-sustaining, or indicated for preventing or treating a debilitating disease or condition, triggers the notice requirement for whoever makes it — and a drug that doesn’t fit those categories can still trigger it if the notifying manufacturer is the only source of it. That second branch is the one people miss: a company that assumes a competitor’s presence in the market exempts it from notifying is reading a version of the rule that stopped applying in 2012.

What FDA does with a shortage notice

A notice isn’t filed and forgotten on FDA’s end either. It can add the product to FDA’s drug shortage list, prompt outreach to other manufacturers of the same or a related product, and, in some cases, support expedited review of a related submission — a different kind of agency response than, say, the three-day clock on a Field Alert Report, but one that depends just as much on the notice actually reaching FDA with enough lead time to act on it.

What actually starts the six-month clock

In practice, the clock starts with whatever decision creates the discontinuation or interruption — a business decision to stop making a product, an active ingredient supplier falling through, or a manufacturing site closing — and the obligation to notify attaches as soon as that decision is made, not once the company is ready to announce it publicly. Sponsors who wait until a public announcement is drafted are often already past the point the clock was supposed to start.

Why this is a regulatory affairs problem, not just a supply chain one

The decision that triggers the clock almost never originates in regulatory affairs — it comes from manufacturing, procurement, or a business unit deciding to sunset a product. What regulatory affairs actually owns is catching that decision early enough for the notice to go out on time, confirming whether the drug falls into a category Section 506C covers at all, and drafting content that actually satisfies the statute rather than a one-line internal memo repurposed for FDA. A team that only hears about a discontinuation once it’s final has already lost the six months the statute assumes it has.

Where people get this wrong

Assuming sole-source status is required to trigger notice

FDASIA removed that limit in 2012. The obligation now reaches every manufacturer of a covered drug category.

Waiting for a final, public decision before notifying

The clock runs from the decision itself, not from the press release or customer letter that follows it.

Sending a notice without the required content

A notice has to explain the reason and the expected duration — a one-line heads-up doesn’t satisfy the statute.

None of this is a reason to dread the notification — it’s a reason to build the decision to discontinue or interrupt manufacture, and the notice that follows it, into the same timeline rather than two separate problems, the same way a well-run team already tracks which postmarket obligations are mandates and which are commitments instead of treating every FDA-facing deadline as interchangeable.

Sources & further reading

21 U.S.C. § 356c — Discontinuance or interruption in the production of certain drugs govinfo.gov
FDA — Drug Shortages fda.gov
Regulatory Academy — How to Read a Field Alert Report regulatoryacademy.com
Regulatory Academy — Postmarketing Requirement vs. Postmarketing Commitment regulatoryacademy.com

This essay is provided for general educational purposes and reflects the regulatory landscape as of its publication date. It is not legal, regulatory, or career advice.